Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) Meeting Abstract
| Authors: | Jhaveri, K. L.; Boni, V.; Sohn, J.; Villanueva-Vásquez, R.; Bardia, A.; Schmid, P.; Lim, E.; Patel, J. M.; Perez-Fidalgo, J. A.; Loi, S.; Im, S. A.; Kshirsagar, S.; Gates, M. R.; Bond, J.; Eng-Wong, J.; Chang, C. W.; Turner, N. C.; Miranda, E. L.; García-Estévez, L.; Bellet, M. |
| Abstract Title: | Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120600122 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.1017 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1017 -- Source: Wos |
